** U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F, QURE.O rise 2.6% to $29.85 premarket, following a 5% gain on Tuesday

** Marty Makary resigned as U.S. FDA commissioner, President Donald Trump said on Tuesday, after weeks of clashes with the White House and health advisers

** Makary faced tensions with drugmakers, including disputes with UniQure over regulatory decisions

** He "was not industry‑friendly," notably after public criticism of QURE data - Truist analyst Danielle Brill

** Makary also drew criticism after declining to approve a cancer treatment from Replimune REPL.O, adding to industry concerns about unpredictability

** Replimune shares advanced 3.9% to $4.25 before the bell

** "Expect an initial positive knee‑jerk reaction from therapeutic investors to Makary's departure .... important to consider the broader ripple effects of these developments" - Brill

** As of last close, QURE up 21.6%, REPL down ~58% YTD